RDHL Stock (Redhill Biopharma Ltd. - American Depositary SharesRedHill Biopharma files to sell 8.86M American Depositary Shares for holders
23.85 MUSD
6.51 MUSD
29.55 M
About Redhill Biopharma Ltd.
Sector
CEO
Dror Ben-Asher
Headquarters
Tel Aviv
Website
Employees (FY)
53
Founded
2009
ISIN
US7574682024
FIGI
BBG003RY91S7
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
RDHL | Good Entry Point | LONGRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobac
NASDAQ: RDHL / RedHill Biopharma LtdHi.
Look at this beauty.
If you want new shares, like wildly and follow wildly.
It is my personal opinion.
It isn't investment advice.
RDHL, enters Downtrend as Momentum drops below 0 level 09/29/20This indicator may be signaling that RDHL's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron A.I.dvisor backtested 85 similar cases where RDHL's Momentum Indicator fell below th
RedHill Biopharma Announces Positive Recommendation from IndepenRDHL: RedHill Biopharma Ltd.
2020-08-27 07:00:10
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 StRDHL: RedHill Biopharma Ltd.
2020-07-31 07:00:10
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
RDHL LongPersonally I think the stock is forming a pullback before another surge, I do believe this stock has the potential to reach $20 in the future.
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical StRDHL: RedHill Biopharma Ltd.
2020-05-08 07:00:10
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
